U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 21 - 22 of 22 results

BEREMAGENE GEPERPAVEC

MORE DETAILS

AQN7K24KQU

structurally diverse
Status:
Possibly Marketed Outside US
Source:
BLA125774
(2023)
Source URL:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe207c8c-04b4-4fdf-87cf-6dbc7eb6e9c2
First approved in 2023
Source:
BLA125774
Source URL:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe207c8c-04b4-4fdf-87cf-6dbc7eb6e9c2
Class:
STRUCTURALLY DIVERSE

HUMAN HERPESVIRUS 3

MORE DETAILS

9885M7D6JP

structurally diverse
Status:
Possibly Marketed Outside US
Source:
NCT00329251: Phase 4 Interventional Completed HIV
(2003)
Source URL:
https://clinicaltrials.gov/ct2/show/NCT00329251
Class:
STRUCTURALLY DIVERSE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966